python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/attachments/dd30785e-eca2-4ba1-92a0-273d6bb366a7/joints.pdf') as pdf: print(f'Pages: {len(pdf.pages)}') for i, page in enumerate(pdf.pages[:3]): print(f'--- PAGE {i+1} ---') print(page.extract_text()[:1000]) "

python3 -c " import pdfplumber all_text = [] with pdfplumber.open('/home/daytona/workspace/attachments/dd30785e-eca2-4ba1-92a0-273d6bb366a7/joints.pdf') as pdf: for i, page in enumerate(pdf.pages): t = page.extract_text() if t: all_text.append(f'=== PAGE {i+1} ===\n{t}') full = '\n'.join(all_text) with open('/home/daytona/workspace/joints_text.txt', 'w') as f: f.write(full) print('Done. Total chars:', len(full)) "

python3 << 'EOF' import pdfplumber all_text = [] with pdfplumber.open('/home/daytona/workspace/attachments/dd30785e-eca2-4ba1-92a0-273d6bb366a7/joints.pdf') as pdf: for i, page in enumerate(pdf.pages): t = page.extract_text() if t and t.strip(): all_text.append(f'PAGE {i+1}: {t.strip()}') print('\n\n'.join(all_text)) EOF

python3 << 'EOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import inch, cm from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable from reportlab.lib.enums import TA_CENTER, TA_LEFT flashcards = [ { "q": "What are the two main types of joints and their key features?", "a": ( "1. Solid (Nonsynovial / Synarthroses): Minimal movement, no joint space.\n" " • Fibrous: Cranial sutures, tooth-to-jaw.\n" " • Cartilaginous (Synchondroses): Sternum-rib symphyses, pelvic bones.\n\n" "2. Cavitated (Synovial): Wide range of motion, lined by synovial membrane.\n" " • Type A synoviocytes: Macrophages (phagocytic).\n" " • Type B synoviocytes: Fibroblast-like, synthesize hyaluronic acid.\n" " • Synovial fluid: Plasma filtrate with hyaluronic acid (lubricant + nutrient provider)." ) }, { "q": "What is hyaline cartilage and what are its components?", "a": ( "Elastic shock absorber and wear-resistant surface. NO blood supply, lymphatics, or innervation.\n\n" "Composition:\n" " • Water: 70%\n" " • Type II collagen: 10% → Resists tensile stress\n" " • Proteoglycans: 8% → Limit friction & resist compression\n" " • Chondrocytes: Synthesize & enzymatically digest matrix; secrete degradative enzymes (inactive form)" ) }, { "q": "What is Osteoarthritis (OA)?", "a": ( "Degenerative joint disease — most common joint disease.\n" " • Structural failure of synovial joints.\n" " • Intrinsic cartilage disorder (NOT primarily inflammatory).\n" " • Chondrocytes respond to mechanical & biochemical stress → matrix breakdown & failure to repair.\n" " • Inflammatory mediators worsen damage over time." ) }, { "q": "What are the types of OA and its epidemiology?", "a": ( "Types:\n" " • Primary (Idiopathic): Insidious onset, no clear cause, usually oligoarticular.\n" " • Secondary: Younger individuals with predisposing factors (joint deformities, prior injury, systemic disease).\n\n" "Epidemiology:\n" " • Prevalence increases exponentially after age 50.\n" " • ~40% of people >70 years are affected." ) }, { "q": "What are the pathogenesis mechanisms in OA?", "a": ( " • Articular cartilage: Low-friction surface; resists compression via Type II collagen and proteoglycans.\n" " • Biomechanical stress + genetic factors → OA development.\n" " • Chondrocyte dysfunction: Degradation exceeds synthesis; MMPs degrade Type II collagen.\n" " • Inflammatory mediators: TGF-β (induces MMPs), TNF, prostaglandins, nitric oxide → matrix destruction.\n" " • Late stage: Chondrocyte loss + severe matrix degradation." ) }, { "q": "What are the morphological changes in OA?", "a": ( "Early Changes:\n" " • Chondrocyte proliferation → cluster formation.\n" " • Increased matrix water content; reduced proteoglycan concentration.\n" " • Collagen cleavage → fissures & surface clefts.\n\n" "Progression:\n" " • Full-thickness cartilage sloughing.\n" " • Loose fragments = 'joint mice'.\n" " • Bone eburnation (polished ivory appearance).\n" " • Subchondral cysts (synovial fluid forced into bone).\n" " • Osteophytes at joint margins.\n" " • Synovium: mildly congested & fibrotic." ) }, { "q": "What is the clinical presentation of OA and its management?", "a": ( "Clinical Features (typically >50 years):\n" " • Joint pain worsens with use (unlike RA).\n" " • Morning stiffness, crepitus, limited range of motion.\n" " • Heberden nodes: Osteophytes at distal interphalangeal joints (common in women).\n" " • Osteophyte impingement → radicular pain, muscle spasms/atrophy.\n" " • Common joints: Hips, knees, lower lumbar/cervical spine, DIP/PIP, 1st carpometacarpal, 1st tarsometatarsal.\n\n" "Management:\n" " • No curative treatment. Pain management, NSAIDs, intra-articular corticosteroids, arthroplasty (severe)." ) }, { "q": "What is Rheumatoid Arthritis (RA)?", "a": ( "Chronic inflammatory autoimmune disorder, primarily affecting synovial joints.\n" "Progresses to: Inflammatory synovitis → Cartilage destruction → Joint ankylosis (fusion).\n\n" "Extra-articular involvement: Skin, heart, blood vessels, lungs.\n\n" "Epidemiology:\n" " • ~1% prevalence in the U.S.\n" " • 3x more common in women.\n" " • Peak incidence: 30s–50s." ) }, { "q": "What is the pathogenesis of Rheumatoid Arthritis?", "a": ( "CD4+ T cells mediate inflammation & tissue damage:\n" " • TH1 → IFN-γ → Activates macrophages & synovial cells.\n" " • TH17 → IL-17 → Recruits neutrophils & monocytes.\n" " • T cells express RANKL → Osteoclast stimulation → Bone resorption.\n" " • Macrophages release TNF & IL-1 → Protease secretion → Cartilage destruction.\n\n" "TNF is strongly implicated → TNF inhibitors are effective treatments." ) }, { "q": "What autoantibodies are found in RA and what is their significance?", "a": ( "1. ACPA (Anti-citrullinated protein antibodies):\n" " • Target citrullinated fibrinogen, Type II collagen, α-enolase, vimentin.\n" " • Present in ~70% of RA patients.\n" " • Contribute to chronic disease.\n\n" "2. Rheumatoid Factor (RF):\n" " • IgM/IgA autoantibodies against Fc portion of IgG.\n" " • Present in ~80% of RA patients (also seen in non-RA individuals).\n" " • May deposit in joints as immune complexes.\n\n" "Genetic risk: HLA class II locus (ACPA-positive RA), PTPN22 mutation.\n" "Environmental triggers: Infections, smoking → promote citrullination of self-proteins." ) }, { "q": "What are the morphological features of RA?", "a": ( "Symmetric arthritis, mainly small joints of hands & feet.\n\n" "Gross: Edematous, thickened, hyperplastic synovium with villi.\n\n" "Histologic:\n" " • Synovial cell hyperplasia.\n" " • Dense infiltrates: CD4+ T cells, B cells, plasma cells, dendritic cells, macrophages.\n" " • Increased vascularity; neutrophils & fibrin aggregates.\n" " • Osteoclastic erosion → periarticular erosions & subchondral cysts.\n\n" "Pannus: Edematous synovium + inflammatory cells + granulation tissue → overgrows cartilage → fibrous then bony ankylosis.\n\n" "Rheumatoid Nodules: Subcutaneous (forearm, elbows, occiput) — resemble necrotizing granulomas." ) }, { "q": "What is the clinical course of Rheumatoid Arthritis?", "a": ( "Diagnosis: Distinguished by ACPA & radiographic findings.\n\n" "Onset: ~50% start insidiously (malaise, fatigue, MSK pain before joint involvement).\n\n" "Pattern: Symmetrical — hands, feet, wrists, ankles, elbows, knees (MCP & PIP joints).\n\n" "Symptoms: Swollen, warm, painful joints; morning stiffness (worsens with inactivity).\n\n" "Deformities: Ulnar deviation, swan-neck deformity, boutonnière deformity.\n\n" "Radiology: Effusions, juxtaarticular osteopenia, erosions, joint space narrowing.\n\n" "Treatment: Corticosteroids, methotrexate, TNF antagonists (increase infection risk including TB)." ) }, { "q": "What is Juvenile Idiopathic Arthritis (JIA)?", "a": ( "Group of unknown-cause arthritis disorders:\n" " • Onset <16 years, persists ≥6 weeks.\n\n" "Differences from RA:\n" " 1. Oligoarthritis more common.\n" " 2. Systemic disease more frequent.\n" " 3. Large joints affected more than small joints.\n" " 4. Absence of rheumatoid nodules & RF.\n" " 5. ANA positivity common.\n\n" "Pathogenesis: Similar to RA; HLA & PTPN22 variants; TH1 & TH17 cells.\n" "Treatment: Similar to RA; IL-6 receptor antibody for systemic cases.\n" "Prognosis: Highly variable; 10% develop severe functional disability." ) }, { "q": "What are Seronegative Spondyloarthropathies?", "a": ( "Group of immune-mediated disorders sharing:\n" " • Absence of rheumatoid factor (seronegative).\n" " • Pathologic changes at ligament attachments (enthesitis), not synovium.\n" " • Sacroiliac joint involvement.\n" " • HLA-B27 association.\n" " • Bony proliferation → Joint ankylosis.\n\n" "Pathogenesis: T-cell response to unidentified antigen (possibly infectious).\n\n" "Includes: Ankylosing spondylitis, Reactive arthritis, Psoriatic arthritis, IBD-associated arthritis." ) }, { "q": "What is Ankylosing Spondylitis?", "a": ( "Prototypical spondyloarthritis.\n" " • Articular cartilage destruction & bony ankylosis, especially sacroiliac joints.\n" " • Onset: 2nd/3rd decade — lower back pain, spinal immobility.\n" " • Peripheral joint involvement (hips, knees, shoulders) in ~1/3 of cases.\n" " • ~90% of patients are HLA-B27 positive (mechanism unclear).\n" " • Treatment: Anti-IL-17 therapy has shown efficacy." ) }, { "q": "What is Reactive Arthritis?", "a": ( "Classic triad:\n" " 1. Arthritis.\n" " 2. Nongonococcal urethritis/cervicitis.\n" " 3. Conjunctivitis.\n\n" " • Mainly men in 20s–30s; ~80% HLA-B27 positive.\n" " • Triggered by prior Chlamydia (GU) or GI infection (Shigella, Salmonella, Yersinia, Campylobacter).\n" " • Symptoms develop weeks after infection: Low back pain; asymmetric ankle, knee, foot involvement.\n" " • Severe chronic cases can mimic ankylosing spondylitis." ) }, { "q": "What are the common causes of Infectious (Septic) Arthritis?", "a": ( "Routes of infection:\n" " • Hematogenous spread (most common).\n" " • Direct inoculation (trauma).\n" " • Contiguous spread from osteomyelitis.\n\n" "Common pathogens by group:\n" " • Neonates/<2 yr: H. influenzae, S. aureus.\n" " • Older children/adults: S. aureus (most common).\n" " • Sexually active: Gonococcus (mainly women).\n" " • Sickle cell disease: Salmonella.\n" " • Complement deficiency (C5–C9): Gonococcal susceptibility.\n\n" "Most common joint: Knee (90%), then hip, shoulder, elbow, wrist.\n" "Dx: Joint aspiration (purulent fluid). Rx: Prompt antibiotics to prevent cartilage destruction." ) }, { "q": "What is Lyme Arthritis and how is it managed?", "a": ( "Causative agent: Borrelia burgdorferi, transmitted by deer ticks.\n\n" "Three stages:\n" " 1. Early localized: Skin (erythema migrans).\n" " 2. Early disseminated: Cranial nerves, heart, meninges.\n" " 3. Late stage (weeks–months): Arthritis (especially knees).\n\n" " • Arthritis in <10% with early treatment; 60–80% in untreated cases.\n" " • Spirochetes detected in only ~25% of joints.\n" " • Diagnosis: Serologic testing for anti-Borrelia antibodies.\n\n" "Treatment: Antibiotics (90% cure rate). PTLDS: Fatigue, cognitive complaints, chronic pain after treatment.\n" "Morphology: Synoviocyte hyperplasia, fibrin deposition, onion-skin arterial thickening. Severe cases resemble RA." ) }, { "q": "What is Gout and what are its types?", "a": ( "Recurrent attacks of acute arthritis due to monosodium urate (MSU) crystal deposition.\n" "Common feature: Excessive uric acid in tissues & fluids (hyperuricemia >6.8 mg/dL).\n\n" "Types:\n" " • Primary Gout (90%): Unknown cause; most commonly reduced urate excretion.\n" " • Secondary Gout: Due to underlying disease.\n" " - Increased production: Tumor lysis syndrome.\n" " - Decreased excretion: Chronic renal disease.\n\n" "HGPRT deficiency → Increased uric acid. Complete deficiency → Lesch-Nyhan syndrome." ) }, { "q": "What is the inflammation mechanism in Gout?", "a": ( "Urate crystals precipitate → Cytokine production → Leukocyte recruitment.\n" " → Macrophages & neutrophils phagocytose crystals → Inflammasome activation.\n" " → Caspase-1 activated → IL-1β release (key proinflammatory mediator).\n" " → Further cytokine & complement activation → Acute arthritis.\n\n" "Repeated attacks → Tophi formation → Severe cartilage damage & joint dysfunction.\n\n" "Risk factors: Male sex, obesity, metabolic syndrome, alcohol, renal failure, age >30, thiazides, HGPRT mutations (X-linked)." ) }, { "q": "What are the morphological changes in Gout?", "a": ( "1. Acute arthritis:\n" " • Dense inflammatory infiltrates in synovium.\n" " • Urate crystals: Long, slender, needle-shaped, NEGATIVELY birefringent.\n" " • Edematous synovium with lymphocytes, plasma cells, macrophages.\n\n" "2. Chronic tophaceous arthritis:\n" " • Chalky crystal deposits; hyperplastic fibrotic synovium forms pannus → cartilage destruction.\n\n" "3. Tophi:\n" " • Urate crystal aggregates + foreign-body giant cell reaction.\n" " • Located in cartilage, ligaments, tendons, bursae.\n\n" "4. Gouty nephropathy:\n" " • Urate crystals/tophi in renal tubules/interstitium.\n" " • May cause nephrolithiasis & pyelonephritis." ) }, { "q": "What are the four clinical stages of Gout?", "a": ( "1. Asymptomatic hyperuricemia:\n" " • Emerges around puberty (men) & after menopause (women).\n\n" "2. Acute arthritis:\n" " • Sudden onset excruciating joint pain, warmth, swelling.\n" " • Monoarticular in 50% (first MTP joint most common — podagra).\n" " • Untreated: Lasts hours to weeks, resolves completely.\n\n" "3. Asymptomatic intercritical period:\n" " • Symptom-free between attacks; attacks recur at decreasing intervals → polyarticular.\n\n" "4. Chronic tophaceous gout (~12 years after first attack):\n" " • Radiographs: Juxtaarticular erosion & joint space loss.\n\n" "Treatment: Lifestyle modification, NSAIDs, xanthine oxidase inhibitors (urate-lowering therapy)." ) }, { "q": "What is Pseudogout and how does it differ from Gout?", "a": ( "Definition: Deposition of calcium pyrophosphate dihydrate (CPPD) crystals → Joint inflammation.\n\n" "Epidemiology: Most common >50 years; equal gender/race distribution.\n\n" "Types: Sporadic (idiopathic), Hereditary (autosomal dominant, pyrophosphate transport channel mutation), Secondary (joint damage, hyperparathyroidism, hemochromatosis, diabetes).\n\n" "Crystal characteristics:\n" " • Rhomboid-shaped (0.5–5 µm); POSITIVELY birefringent (vs. gout = negative).\n" " • Chalky white, blue-purple on histology.\n" " • First form in articular cartilage, menisci, intervertebral discs.\n\n" "Clinical: Can mimic OA or RA; commonly affects knees, wrists, elbows, shoulders, ankles.\n" "50% eventually develop significant joint damage.\n" "Treatment: Supportive care only; no treatment prevents crystal formation." ) }, { "q": "What is Tenosynovial Giant Cell Tumor?", "a": ( "Two variants:\n\n" "1. Diffuse variant:\n" " • Synovium transforms into tangled mat with red-brown folds, fingerlike projections & nodules.\n" " • Most commonly affects the knee (~80% of cases).\n" " • Symptoms: Pain, locking, recurrent swelling (resembles monoarticular arthritis), palpable mass.\n\n" "2. Localized (Nodular) variant:\n" " • Well-circumscribed mass; commonly affects the hand.\n" " • Solitary, slow-growing, painless mass.\n\n" "Histology (both): Polygonal neoplastic cells + macrophages with hemosiderin & foamy lipid + multinucleated cells.\n\n" "Treatment: Surgical excision. Recurrence more common in diffuse variant.\n" "Investigational: M-CSF pathway antagonists for unresectable cases." ) }, { "q": "OA vs RA: Key Comparison", "a": ( "Feature | OA | RA\n" "Nature | Degenerative | Autoimmune/Inflammatory\n" "Age | >50 years | 30s–50s\n" "Gender | Both | 3x more women\n" "Joints | DIP, hips, knees, | MCP, PIP, wrists,\n" " | spine, CMC | ankles, elbows, knees\n" "Pattern | Asymmetric, few | Symmetric, multiple\n" "Stiffness | Worsens with use | Worsens with inactivity\n" "Serologic | Negative | RF+, ACPA+\n" "Deformity | Heberden nodes | Ulnar deviation,\n" " | No ankylosis | swan-neck, boutonnière\n" "Pathology | Cartilage breakdown | Pannus, synovitis\n" "Inflammation | Mild, secondary | Primary & severe" ) }, { "q": "Gout vs Pseudogout: Crystal Comparison", "a": ( "Feature | Gout (MSU) | Pseudogout (CPPD)\n" "Crystal type | Monosodium urate | Calcium pyrophosphate\n" "Shape | Long, needle-shaped | Rhomboid (0.5–5 µm)\n" "Birefringence | Negatively birefringent | Positively birefringent\n" "Color (polarized) | Yellow parallel | Blue parallel\n" "Common joint | 1st MTP (podagra) | Knee, wrist, elbow\n" "Lab finding | Hyperuricemia | CPPD on imaging\n" "Pathogenesis | IL-1β via inflammasome | Inflammasome activation\n" "Gender predominance | Male | Equal\n" "Treatment | NSAIDs, xanthine | Supportive care only\n" " | oxidase inhibitors |" ) }, ] print(f"Total flashcards: {len(flashcards)}") EOF

python3 << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import inch, cm from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, PageBreak from reportlab.lib.enums import TA_CENTER, TA_LEFT import os os.makedirs('/home/daytona/workspace/joints-flashcards', exist_ok=True) output_path = '/home/daytona/workspace/joints-flashcards/Joints_Pathology_Flashcards.pdf' # Page setup doc = SimpleDocTemplate( output_path, pagesize=A4, rightMargin=1.5*cm, leftMargin=1.5*cm, topMargin=1.5*cm, bottomMargin=1.5*cm ) W, H = A4 # Colors DARK_BLUE = colors.HexColor('#1a3a5c') MEDIUM_BLUE = colors.HexColor('#2e6da4') LIGHT_BLUE = colors.HexColor('#dbeafe') ACCENT_GREEN = colors.HexColor('#16a34a') ANSWER_BG = colors.HexColor('#f0f7ff') WHITE = colors.white LIGHT_GRAY = colors.HexColor('#f8fafc') BORDER_COLOR = colors.HexColor('#94b8d8') TEXT_DARK = colors.HexColor('#1e293b') SUBTITLE_COLOR = colors.HexColor('#475569') # Styles styles = getSampleStyleSheet() title_style = ParagraphStyle( 'CoverTitle', parent=styles['Title'], fontSize=28, fontName='Helvetica-Bold', textColor=WHITE, alignment=TA_CENTER, spaceAfter=8 ) subtitle_style = ParagraphStyle( 'CoverSubtitle', parent=styles['Normal'], fontSize=13, fontName='Helvetica', textColor=colors.HexColor('#bfdbfe'), alignment=TA_CENTER, spaceAfter=6 ) card_num_style = ParagraphStyle( 'CardNum', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=WHITE, alignment=TA_LEFT ) question_label_style = ParagraphStyle( 'QLabel', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=MEDIUM_BLUE, alignment=TA_LEFT, spaceAfter=2 ) question_style = ParagraphStyle( 'Question', parent=styles['Normal'], fontSize=13, fontName='Helvetica-Bold', textColor=DARK_BLUE, alignment=TA_LEFT, leading=17, spaceAfter=0 ) answer_label_style = ParagraphStyle( 'ALabel', parent=styles['Normal'], fontSize=9, fontName='Helvetica-Bold', textColor=ACCENT_GREEN, alignment=TA_LEFT, spaceAfter=2 ) answer_style = ParagraphStyle( 'Answer', parent=styles['Normal'], fontSize=10, fontName='Helvetica', textColor=TEXT_DARK, alignment=TA_LEFT, leading=14, spaceAfter=0 ) flashcards = [ { "q": "What are the two main types of joints and their key features?", "a": "1. Solid (Nonsynovial / Synarthroses): Minimal movement, no joint space.\n • Fibrous: Cranial sutures, tooth-to-jaw.\n • Cartilaginous (Synchondroses): Sternum-rib symphyses, pelvic bones.\n\n2. Cavitated (Synovial): Wide range of motion, lined by synovial membrane.\n • Type A synoviocytes: Macrophages (phagocytic).\n • Type B synoviocytes: Fibroblast-like, synthesize hyaluronic acid.\n • Synovial fluid: Plasma filtrate with hyaluronic acid (lubricant + nutrient)." }, { "q": "What is hyaline cartilage and what are its components?", "a": "Elastic shock absorber and wear-resistant surface. NO blood supply, lymphatics, or innervation.\n\nComposition:\n • Water: 70%\n • Type II collagen: 10% → Resists tensile stress\n • Proteoglycans: 8% → Limit friction & resist compression\n • Chondrocytes: Synthesize & enzymatically digest matrix; secrete degradative enzymes (inactive form)" }, { "q": "What is Osteoarthritis (OA)? Define and classify.", "a": "Degenerative joint disease — most common joint disease.\n • Structural failure of synovial joints.\n • Intrinsic cartilage disorder (NOT primarily inflammatory).\n • Chondrocytes respond to mechanical & biochemical stress → matrix breakdown.\n\nTypes:\n • Primary (Idiopathic): Insidious onset, no clear cause, usually oligoarticular.\n • Secondary: Younger individuals with predisposing factors (deformities, prior injury, systemic disease).\n\nPrevalence: Increases exponentially >50 years; ~40% of people >70 affected." }, { "q": "What is the pathogenesis of Osteoarthritis?", "a": " • Articular cartilage: Resists compression via Type II collagen + proteoglycans (viscoelastic).\n • Biomechanical stress + genetic factors → OA.\n • Chondrocyte dysfunction: Degradation > Synthesis; MMPs degrade Type II collagen.\n • Inflammatory mediators: TGF-β (induces MMPs), TNF, prostaglandins, nitric oxide → matrix destruction.\n • Late stage: Chondrocyte loss + severe matrix degradation." }, { "q": "What are the morphological changes in OA?", "a": "Early:\n • Chondrocyte proliferation → clusters; increased matrix water; reduced proteoglycans.\n • Collagen cleavage → fissures & surface clefts.\n\nProgression:\n • Full-thickness cartilage sloughing.\n • 'Joint mice' (loose fragments).\n • Bone eburnation (polished ivory appearance).\n • Subchondral cysts; Osteophytes at joint margins.\n • Synovium: Mildly congested & fibrotic." }, { "q": "What is the clinical presentation and management of OA?", "a": "Symptoms (typically >50 years):\n • Joint pain worsens with USE (vs. RA = worsens with inactivity).\n • Morning stiffness, crepitus, limited ROM.\n • Heberden nodes: Osteophytes at DIP joints (common in women).\n • Osteophyte impingement → radicular pain, muscle spasms/atrophy.\n\nCommon joints: Hips, knees, lumbar/cervical spine, DIP/PIP, 1st CMC, 1st tarsometatarsal.\n\nNote: OA does NOT cause joint fusion (ankylosis).\n\nManagement: Pain relief, NSAIDs, intra-articular corticosteroids, arthroplasty (severe cases)." }, { "q": "What is Rheumatoid Arthritis (RA)?", "a": "Chronic inflammatory autoimmune disorder, primarily affecting synovial joints.\nProgresses to: Inflammatory synovitis → Cartilage destruction → Joint ankylosis (fusion).\n\nExtra-articular: Skin, heart, blood vessels, lungs.\n\nEpidemiology:\n • ~1% prevalence in the U.S.\n • 3x more common in women.\n • Peak incidence: 30s–50s." }, { "q": "What is the pathogenesis of Rheumatoid Arthritis?", "a": "CD4+ T cells mediate inflammation:\n • TH1 → IFN-γ → Activates macrophages & synovial cells.\n • TH17 → IL-17 → Recruits neutrophils & monocytes.\n • T cells express RANKL → Osteoclast activation → Bone resorption.\n • Macrophages release TNF & IL-1 → Proteases → Cartilage destruction.\n\nTNF is key mediator → TNF inhibitors (anti-TNF) are effective treatments." }, { "q": "What autoantibodies are found in RA?", "a": "1. ACPA (Anti-citrullinated protein antibodies):\n • Target citrullinated fibrinogen, Type II collagen, α-enolase, vimentin.\n • Present in ~70% of RA patients; contribute to chronic disease.\n\n2. Rheumatoid Factor (RF):\n • IgM/IgA against Fc portion of IgG; ~80% of RA patients.\n • May deposit in joints as immune complexes.\n\nGenetics: HLA class II (ACPA+ RA), PTPN22 mutation.\nEnvironmental: Infections, smoking → citrullination of self-proteins → autoimmunity." }, { "q": "What are the morphological features of Rheumatoid Arthritis?", "a": "Symmetric arthritis: Small joints of hands & feet.\n\nGross: Edematous, thickened, hyperplastic synovium with villi.\n\nHistology:\n • Synovial cell hyperplasia.\n • Dense infiltrates: CD4+ T cells, B cells, plasma cells, macrophages.\n • Increased vascularity; neutrophils & fibrin aggregates.\n • Osteoclastic erosion → periarticular erosions & subchondral cysts.\n\nPannus: Synovium + inflammatory cells + granulation tissue → overgrows cartilage → fibrous → bony ankylosis.\n\nRheumatoid Nodules: Subcutaneous (forearm, elbows, occiput) — resemble necrotizing granulomas." }, { "q": "What is the clinical course of RA and its treatment?", "a": "Diagnosis: Distinguished by ACPA & radiographic findings.\n\nOnset: ~50% insidious (malaise, fatigue before joint involvement).\n\nPattern: SYMMETRIC — hands, feet, wrists, ankles, elbows, knees (MCP & PIP joints).\n\nSymptoms: Swollen, warm, painful joints; morning stiffness (worsens with inactivity).\n\nDeformities: Ulnar deviation, swan-neck deformity, boutonnière deformity.\n\nRadiology: Effusions, juxtaarticular osteopenia, erosions, joint space narrowing.\n\nTreatment: Corticosteroids, methotrexate, TNF antagonists (increase TB infection risk)." }, { "q": "What is Juvenile Idiopathic Arthritis (JIA)?", "a": "Onset <16 years, persists ≥6 weeks. Unknown cause.\n\nDifferences from RA:\n 1. Oligoarthritis more common.\n 2. Systemic disease more frequent.\n 3. Large joints >small joints.\n 4. Absence of rheumatoid nodules & RF.\n 5. ANA positivity common.\n\nPathogenesis: Similar to RA; HLA & PTPN22 variants; TH1 & TH17 cells.\n\nTreatment: Similar to RA; IL-6 receptor antibody for systemic cases.\n\nPrognosis: Highly variable; 10% develop severe functional disability." }, { "q": "What are Seronegative Spondyloarthropathies? List their shared features.", "a": "Group of immune-mediated disorders sharing:\n • Absence of rheumatoid factor (seronegative).\n • Pathologic changes at ligament attachments (enthesitis), not synovium.\n • Sacroiliac joint involvement.\n • HLA-B27 association.\n • Bony proliferation → Joint ankylosis.\n\nPathogenesis: T-cell response to unidentified antigen (possibly infectious).\n\nIncludes:\n • Ankylosing spondylitis\n • Reactive arthritis\n • Psoriatic arthritis\n • IBD-associated arthritis" }, { "q": "What is Ankylosing Spondylitis?", "a": "Prototypical spondyloarthritis.\n • Articular cartilage destruction & bony ankylosis — especially sacroiliac joints.\n • Onset: 2nd/3rd decade → lower back pain, spinal immobility.\n • Peripheral joint involvement (hips, knees, shoulders) in ~1/3 of cases.\n • ~90% of patients are HLA-B27 positive (mechanism unclear).\n\nTreatment: Anti-IL-17 therapy has shown efficacy." }, { "q": "What is Reactive Arthritis? (formerly Reiter's Syndrome)", "a": "Classic triad:\n 1. Arthritis\n 2. Nongonococcal urethritis/cervicitis\n 3. Conjunctivitis\n\n • Mainly men in 20s–30s; ~80% HLA-B27 positive.\n • Triggered by prior genitourinary (Chlamydia) or GI infection (Shigella, Salmonella, Yersinia, Campylobacter).\n • Symptoms develop weeks after infection.\n • Pattern: Low back pain; asymmetric ankle, knee, foot involvement.\n • Severe chronic cases can mimic ankylosing spondylitis." }, { "q": "What are the common causes and features of Septic (Suppurative) Arthritis?", "a": "Routes: Hematogenous spread, direct inoculation (trauma), contiguous spread from osteomyelitis.\n\nPathogens by group:\n • Neonates/<2 yr: H. influenzae, S. aureus.\n • Older children/adults: S. aureus (most common).\n • Sexually active: Gonococcus (mainly women).\n • Sickle cell disease: Salmonella.\n • C5–C9 deficiency: Increased gonococcal susceptibility.\n\nPresentation: Sudden onset painful, warm, swollen joint; fever, leukocytosis.\nMost common joint: Knee (90%), then hip, shoulder, elbow, wrist.\nDiagnosis: Joint aspiration (purulent fluid).\nTreatment: Prompt antibiotics to prevent permanent cartilage destruction." }, { "q": "What is Lyme Arthritis? Describe its stages and management.", "a": "Causative agent: Borrelia burgdorferi; transmitted by deer ticks.\n\n3 Stages:\n 1. Early localized: Skin (erythema migrans).\n 2. Early disseminated: Cranial nerves, heart, meninges.\n 3. Late stage (weeks–months): Arthritis (especially knees).\n\n • Arthritis in <10% with early treatment; 60–80% untreated.\n • Spirochetes detected in ~25% of joints.\n • Dx: Serologic testing (anti-Borrelia antibodies).\n\nTreatment: Antibiotics (90% cure rate).\nMorphology: Synoviocyte hyperplasia, fibrin deposition, onion-skin arterial thickening.\nPTLDS: Fatigue, cognitive complaints, chronic joint pain post-treatment." }, { "q": "What is Gout? Types and pathogenesis of hyperuricemia.", "a": "Recurrent attacks of acute arthritis due to monosodium urate (MSU) crystal deposition.\nRequires hyperuricemia (>6.8 mg/dL) but not sufficient alone.\n\nTypes:\n • Primary Gout (90%): Reduced urate excretion (cause unknown).\n • Secondary Gout: Due to underlying disease.\n - Increased production: Tumor lysis syndrome, HGPRT deficiency.\n - Decreased excretion: Chronic renal disease.\n\nHGPRT deficiency → Lesch-Nyhan syndrome (complete deficiency).\n\nUric acid = end product of purine metabolism; excreted by kidney." }, { "q": "What is the inflammation mechanism in Gout and its risk factors?", "a": "Mechanism:\n Urate crystals → Cytokine production → Leukocyte recruitment\n → Macrophages/neutrophils phagocytose crystals → Inflammasome activation\n → Caspase-1 activated → IL-1β release → Acute arthritis\n → Repeated attacks → Tophi → Cartilage damage\n\nRisk Factors:\n • Male sex, obesity, metabolic syndrome, alcohol intake.\n • Renal failure, age >30 years.\n • HGPRT mutations (X-linked).\n • Age & duration of hyperuricemia (20–30 years before onset).\n • Thiazide diuretics (reduce urate excretion)." }, { "q": "What are the morphological changes in Gout?", "a": "1. Acute arthritis:\n • Dense inflammatory infiltrates in synovium.\n • Urate crystals: Long, needle-shaped, NEGATIVELY birefringent.\n\n2. Chronic tophaceous arthritis:\n • Chalky crystal deposits; fibrotic synovium forms pannus.\n\n3. Tophi:\n • Urate crystals + foreign-body giant cell reaction.\n • Found in cartilage, ligaments, tendons, bursae.\n\n4. Gouty nephropathy:\n • Urate crystals/tophi in renal tubules/interstitium.\n • May cause nephrolithiasis & pyelonephritis." }, { "q": "What are the four clinical stages of Gout and its treatment?", "a": "Stage 1: Asymptomatic hyperuricemia (from puberty in men, menopause in women).\n\nStage 2: Acute arthritis — sudden excruciating pain, warmth, swelling.\n • Monoarticular in 50% (1st MTP joint = podagra).\n • Untreated: Lasts hours to weeks, resolves completely.\n\nStage 3: Asymptomatic intercritical period — attacks recur at decreasing intervals, become polyarticular.\n\nStage 4: Chronic tophaceous gout (~12 years after first attack).\n • Radiographs: Juxtaarticular erosion & joint space loss.\n\nTreatment: Lifestyle modification, NSAIDs, xanthine oxidase inhibitors (allopurinol)." }, { "q": "What is Pseudogout (CPPD Disease)?", "a": "Definition: Deposition of calcium pyrophosphate dihydrate (CPPD) crystals → Joint inflammation.\n\nEpidemiology: Most common >50 years; equal gender/race distribution.\n\nTypes: Sporadic, Hereditary (autosomal dominant, pyrophosphate transport channel mutation), Secondary (joint damage, hyperparathyroidism, hemochromatosis, diabetes).\n\nCrystal characteristics:\n • Rhomboid-shaped (0.5–5 µm); POSITIVELY birefringent.\n • Chalky white; blue-purple on histology.\n • Form first in articular cartilage, menisci, intervertebral discs.\n\nClinical: Mimics OA or RA; knees, wrists, elbows, shoulders, ankles.\n50% eventually develop significant joint damage.\nTreatment: Supportive care only." }, { "q": "What is Tenosynovial Giant Cell Tumor?", "a": "Two variants:\n\n1. Diffuse variant:\n • Synovium → tangled mat with red-brown folds, fingerlike projections & nodules.\n • Mainly affects the knee (~80%).\n • Symptoms: Pain, locking, recurrent swelling, palpable mass.\n • Recurrence more common after surgery.\n\n2. Localized (Nodular) variant:\n • Well-circumscribed mass; mainly affects the hand.\n • Solitary, slow-growing, painless mass.\n\nHistology (both): Polygonal neoplastic cells + macrophages with hemosiderin & foamy lipid + multinucleated cells.\n\nTreatment: Surgical excision.\nInvestigational: M-CSF pathway antagonists for unresectable cases." }, { "q": "OA vs RA: Key Differences", "a": "FEATURE | OA | RA\nNature | Degenerative | Autoimmune\nAge | >50 years | 30s–50s\nGender | Both | 3x more women\nJoints | DIP, hips, knees, spine | MCP, PIP, wrists, ankles\nPattern | Asymmetric, oligoarticular| Symmetric, polyarticular\nStiffness | Worsens with USE | Worsens with INACTIVITY\nSerologic | Negative | RF+, ACPA+\nDeformity | Heberden nodes; NO fusion | Ulnar deviation, swan-neck\nPathology | Cartilage breakdown | Pannus, synovitis\nInflammation | Mild, secondary | Primary & severe\nTx | NSAIDs, arthroplasty | MTX, TNF inhibitors" }, { "q": "Gout vs Pseudogout: Crystal Comparison", "a": "FEATURE | GOUT (MSU) | PSEUDOGOUT (CPPD)\nCrystal | Monosodium urate | Calcium pyrophosphate\nShape | Long, needle-shaped | Rhomboid\nBirefringence | NEGATIVE | POSITIVE\nCommon joint | 1st MTP (podagra) | Knee, wrist, elbow\nLab | Hyperuricemia | CPPD on imaging\nAge | >30 years | >50 years\nGender | Predominantly male | Equal\nMechanism | IL-1β, inflammasome | Inflammasome activation\nTreatment | NSAIDs, xanthine | Supportive care only\n | oxidase inhibitors |" }, { "q": "Crystal-Induced Arthritis: Overview", "a": "Caused by articular crystal deposits.\n\nEndogenous crystals:\n • Monosodium urate (MSU) → Gout\n • Calcium pyrophosphate dihydrate (CPPD) → Pseudogout\n • Basic calcium phosphate\n\nExogenous crystals:\n • Silicone, polyethylene, methyl methacrylate (from prosthetic joints)\n\nPathogenesis:\n • All crystals trigger inflammasome activation → IL-1β → acute inflammation\n • Repeated attacks → Cartilage destruction & joint damage\n\nKey distinction:\n • Gout crystals = Negatively birefringent (needle-shaped)\n • Pseudogout crystals = Positively birefringent (rhomboid)" }, ] def make_card(num, q, a): total = len(flashcards) card_data = [ # Header row [ Table( [[ Paragraph(f"CARD {num}/{total}", card_num_style), Paragraph("JOINTS PATHOLOGY", ParagraphStyle('RightH', parent=card_num_style, alignment=2)) ]], colWidths=[4*cm, 13*cm], style=TableStyle([ ('BACKGROUND', (0,0), (-1,-1), DARK_BLUE), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ('LEFTPADDING', (0,0), (0,0), 10), ('RIGHTPADDING', (1,0), (1,0), 10), ('TOPPADDING', (0,0), (-1,-1), 6), ('BOTTOMPADDING', (0,0), (-1,-1), 6), ]) ) ], # Question row [ Table( [[ Paragraph("QUESTION", question_label_style), Paragraph(q, question_style), ]], colWidths=[17*cm], style=TableStyle([ ('BACKGROUND', (0,0), (-1,-1), LIGHT_BLUE), ('LEFTPADDING', (0,0), (-1,-1), 14), ('RIGHTPADDING', (0,0), (-1,-1), 14), ('TOPPADDING', (0,0), (-1,-1), 12), ('BOTTOMPADDING', (0,0), (-1,-1), 12), ]) ) ], # Divider [HRFlowable(width="100%", thickness=1, color=BORDER_COLOR)], # Answer row [ Table( [[ Paragraph("ANSWER", answer_label_style), Paragraph(a.replace('\n', '<br/>'), answer_style), ]], colWidths=[17*cm], style=TableStyle([ ('BACKGROUND', (0,0), (-1,-1), ANSWER_BG), ('LEFTPADDING', (0,0), (-1,-1), 14), ('RIGHTPADDING', (0,0), (-1,-1), 14), ('TOPPADDING', (0,0), (-1,-1), 12), ('BOTTOMPADDING', (0,0), (-1,-1), 14), ]) ) ], ] card = Table( card_data, colWidths=[17.5*cm], style=TableStyle([ ('BOX', (0,0), (-1,-1), 1.5, BORDER_COLOR), ('ROWBACKGROUNDS', (0,0), (-1,-1), [None, None, None, None]), ('LEFTPADDING', (0,0), (-1,-1), 0), ('RIGHTPADDING', (0,0), (-1,-1), 0), ('TOPPADDING', (0,0), (-1,-1), 0), ('BOTTOMPADDING', (0,0), (-1,-1), 0), ('ROUNDEDCORNERS', [8]), ]) ) return card # Build content story = [] # Cover page cover_data = [[ Table( [ [Paragraph("JOINTS PATHOLOGY", title_style)], [Paragraph("Flashcard Study Set", subtitle_style)], [Paragraph("Dr. Parisa Shamshiripour, M.D., Ph.D., AP/CP", ParagraphStyle('auth', parent=subtitle_style, fontSize=11))], [Spacer(1, 0.3*cm)], [Paragraph(f"26 Flashcards | Complete Topic Coverage", ParagraphStyle('info', parent=subtitle_style, fontSize=10))], [Spacer(1, 0.3*cm)], [Paragraph( "Joint Classification • Hyaline Cartilage • Osteoarthritis • Rheumatoid Arthritis\nJIA • Spondyloarthropathies • Gout • Pseudogout • Infectious Arthritis • Tumors", ParagraphStyle('topics', parent=subtitle_style, fontSize=9, leading=14) )], ], colWidths=[17.5*cm], style=TableStyle([ ('BACKGROUND', (0,0), (-1,-1), DARK_BLUE), ('ALIGN', (0,0), (-1,-1), 'CENTER'), ('VALIGN', (0,0), (-1,-1), 'MIDDLE'), ('TOPPADDING', (0,0), (-1,-1), 18), ('BOTTOMPADDING', (0,0), (-1,-1), 18), ('ROUNDEDCORNERS', [12]), ]) ) ]] cover_table = Table(cover_data, colWidths=[17.5*cm]) story.append(cover_table) story.append(Spacer(1, 0.8*cm)) # Section headers mapping sections = { 1: "JOINT ANATOMY & CLASSIFICATION", 3: "OSTEOARTHRITIS (OA)", 7: "RHEUMATOID ARTHRITIS (RA)", 12: "JUVENILE & SPONDYLOARTHROPATHIES", 15: "INFECTIOUS ARTHRITIS", 18: "CRYSTAL-INDUCED ARTHRITIS", 23: "TUMORS & COMPARISONS", } section_style = ParagraphStyle( 'SectionHeader', parent=styles['Normal'], fontSize=11, fontName='Helvetica-Bold', textColor=WHITE, alignment=TA_CENTER, spaceAfter=6, spaceBefore=4, ) for i, fc in enumerate(flashcards, 1): if i in sections: sect_table = Table( [[Paragraph(f" {sections[i]} ", section_style)]], colWidths=[17.5*cm], style=TableStyle([ ('BACKGROUND', (0,0), (-1,-1), MEDIUM_BLUE), ('TOPPADDING', (0,0), (-1,-1), 7), ('BOTTOMPADDING', (0,0), (-1,-1), 7), ('ROUNDEDCORNERS', [6]), ]) ) if i > 1: story.append(Spacer(1, 0.4*cm)) story.append(sect_table) story.append(Spacer(1, 0.3*cm)) card = make_card(i, fc['q'], fc['a']) story.append(card) story.append(Spacer(1, 0.4*cm)) doc.build(story) print(f"PDF created at: {output_path}") PYEOF